Emeritus Professor Stephen Mahler
Emeritus Professor

Stephen Mahler

Email: 

Background

Professor Stephen Mahler is a Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology and Director of the Australian Research Council Training Centre for Biopharmaceutical Innovation (CBI), University of Queensland. Professor Mahler is a biotechnologist with a focus on R&D of recombinant-DNA derived protein biopharmaceuticals, drug delivery systems and nanomedicines. Professor Mahler has a record of translational research success and engages extensively with industry associated with the biomedical sciences both nationally and internationally.

Research within CBI covers three thematic research areas; discovery of new biopharmaceuticals, engineering cells for production of protein-based biopharmaceuticals and advanced manufacturing for industrial production. A current research interest is at the interface of the life sciences and materials science, using a synthetic biology approach for creating novel therapeutic entities as well as new systems for drug delivery.

Professor Mahler has a strong interest in education and training and was formerly Head of the Chemical and Biological Engineering Plan at the University of Queensland (2010-2016). Other educational initiatives include development of Masters Programs and a Continuing Professional Development program in the area of biopharmaceuticals. The CPD program is available to stakeholders in the industry, both in Australia and internationally.

Availability

Emeritus Professor Stephen Mahler is:
Available for supervision
Media expert

Fields of research

Biological Sciences Industrial biotechnology Medical biotechnology

Qualifications

  • Doctor of Philosophy, The University of Queensland

Research impacts

Professor Mahler has a strong engagement with industry both nationally and internationally, that through collaborative research has led to some significant translational outcomes including clinical trial of biopharmaceutical drug candidates through to approval. The Australian Research Council Training Centre for Biopharmaceutical Innovation is a consortium of partners including government, the University of Queensland and several industry partners, with a goal of contributing to the transformation of the biopharmaceutical industry. Through the Centre and the CPD Program in Biopharmaceuticals, Professor Mahler continues to work with stakeholders to ensure a vibrant future for the biopharmaceutical industry in Australia.

Search Professor Stephen Mahler’s works on UQ eSpace

136 works between 1984 and 2024
All (136) Journal Article (100) Book Chapter (13) Conference Publication (18) Other Outputs (5)

1 - 20 of 136 works

2024

Journal Article

Harnessing metabolic plasticity in CHO cells for enhanced perfusion cultivation

Nöbel, Matthias, Barry, Craig, MacDonald, Michael A., Baker, Kym, Shave, Evan, Mahler, Stephen, Munro, Trent, Martínez, Verónica S., Nielsen, Lars K. and Marcellin, Esteban (2024). Harnessing metabolic plasticity in CHO cells for enhanced perfusion cultivation. Biotechnology and Bioengineering, 121 (4), 1371-1383. doi: 10.1002/bit.28613

Harnessing metabolic plasticity in CHO cells for enhanced perfusion cultivation

2024

Journal Article

Amino acid degradation pathway inhibitory by‐products trigger apoptosis in CHO cells

Martínez, Verónica S., Rodriguez, Karen, McCubbin, Timothy, Tong, Junjie, Mahler, Stephen, Shave, Evan, Baker, Kym, Munro, Trent P. and Marcellin, Esteban (2024). Amino acid degradation pathway inhibitory by‐products trigger apoptosis in CHO cells. Biotechnology Journal, 19 (2) ARTN e2300338, e2300338. doi: 10.1002/biot.202300338

Amino acid degradation pathway inhibitory by‐products trigger apoptosis in CHO cells

2023

Conference Publication

Does Acute Psychedelic "Therapy" Persistently Reverse Reward-Related Anhedonia Induced by Early Life Adversity?

Lawson, Kate, Ruiz, Christina, Martinez, Maricela, Coates, Darrien, Weems, Nya, Scofield, Michael and Mahler, Stephen (2023). Does Acute Psychedelic "Therapy" Persistently Reverse Reward-Related Anhedonia Induced by Early Life Adversity?. 62nd Annual Meeting of the American-College-of-Neuropsychopharmacology (ACNP), Tampa Fl, Dec 03-06, 2023. LONDON: SPRINGERNATURE.

Does Acute Psychedelic "Therapy" Persistently Reverse Reward-Related Anhedonia Induced by Early Life Adversity?

2023

Journal Article

Design of polarity-dependent immunosensors based on the structural analysis of engineered antibodies

Islam, Jiaul, Conroy, Paul, Fercher, Christian, Kim, Mijin, Yaari, Zvi, Jones, Martina, Bell, Toby D. M., Caradoc-Davies, Tom, Law, Ruby, Whisstock, James, Heller, Daniel, Mahler, Stephen and Corrie, Simon (2023). Design of polarity-dependent immunosensors based on the structural analysis of engineered antibodies. ACS Chemical Biology, 18 (8), 1863-1871. doi: 10.1021/acschembio.3c00303

Design of polarity-dependent immunosensors based on the structural analysis of engineered antibodies

2022

Journal Article

Evaluation of phage display biopanning strategies for the selection of anti-cell surface receptor antibodies

Panagides, Nadya, Zacchi, Lucia F., Souza, Mitchell J. De, Morales, Rodrigo A. V., Karnowski, Alexander, Liddament, Mark T., Owczarek, Catherine M., Mahler, Stephen M., Panousis, Con, Jones, Martina L. and Fercher, Christian (2022). Evaluation of phage display biopanning strategies for the selection of anti-cell surface receptor antibodies. International Journal of Molecular Sciences, 23 (15) 8470, 8470. doi: 10.3390/ijms23158470

Evaluation of phage display biopanning strategies for the selection of anti-cell surface receptor antibodies

2022

Journal Article

Engineering death resistance in CHO cells for improved perfusion culture

MacDonald, Michael A., Nöbel, Matthias, Martínez, Verónica S., Baker, Kym, Shave, Evan, Gray, Peter P., Mahler, Stephen, Munro, Trent, Nielsen, Lars K. and Marcellin, Esteban (2022). Engineering death resistance in CHO cells for improved perfusion culture. mAbs, 14 (1) e2083465, 1-13. doi: 10.1080/19420862.2022.2083465

Engineering death resistance in CHO cells for improved perfusion culture

2022

Journal Article

Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption

Janowicz, Phillip W., Houston, Zachary H., Bunt, Jens, Fletcher, Nicholas L., Bell, Craig A., Cowin, Gary, Howard, Christopher B., Taslima, Dewan, Westra van Holthe, Nicholas, Prior, Amber, Soh, Vanessa, Ghosh, Saikat, Humphries, James, Huda, Pie, Mahler, Stephen M., Richards, Linda J. and Thurecht, Kristofer J. (2022). Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption. Biomaterials, 283 121416, 121416. doi: 10.1016/j.biomaterials.2022.121416

Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption

2022

Journal Article

Modelling apoptosis resistance in CHO cells with CRISPR‐mediated knock‐outs of Bak1, Bax, and Bok

MacDonald, Michael A., Barry, Craig, Groves, Teddy, Martínez, Verónica S., Gray, Peter P., Baker, Kym, Shave, Evan, Mahler, Stephen, Munro, Trent, Marcellin, Esteban and Nielsen, Lars K. (2022). Modelling apoptosis resistance in CHO cells with CRISPR‐mediated knock‐outs of Bak1, Bax, and Bok. Biotechnology and Bioengineering, 119 (6), 1380-1391. doi: 10.1002/bit.28062

Modelling apoptosis resistance in CHO cells with CRISPR‐mediated knock‐outs of Bak1, Bax, and Bok

2021

Journal Article

Disulfide bond engineering of AppA phytase for increased thermostability requires co-expression of protein disulfide isomerase in Pichia pastoris

Navone, Laura, Vogl, Thomas, Luangthongkam, Pawarisa, Blinco, Jo-Anne, Luna-Flores, Carlos H., Chen, Xiaojing, von Hellens, Juhani, Mahler, Stephen and Speight, Robert (2021). Disulfide bond engineering of AppA phytase for increased thermostability requires co-expression of protein disulfide isomerase in Pichia pastoris. Biotechnology for Biofuels, 14 (1) 80, 80. doi: 10.1186/s13068-021-01936-8

Disulfide bond engineering of AppA phytase for increased thermostability requires co-expression of protein disulfide isomerase in Pichia pastoris

2021

Journal Article

In silico molecular dynamics of human glycophorin A (GPA) extracellular structure

Ekman, Serena, Flower, Robert, Mahler, Stephen, Gould, Alison, Barnard, Ross T., Hyland, Catherine, Jones, Martina, Malde, Alpeshkumar K. and Bui, Xuan T. (2021). In silico molecular dynamics of human glycophorin A (GPA) extracellular structure. Annals of Blood, 6 (June) 11. doi: 10.21037/aob-20-51

In silico molecular dynamics of human glycophorin A (GPA) extracellular structure

2021

Journal Article

Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product

Zacchi, Lucia F., Roche-Recinos, Dinora, Pegg, Cassandra L., Phung, Toan K., Napoli, Mark, Aitken, Campbell, Sandford, Vanessa, Mahler, Stephen M., Lee, Yih Yean, Schulz, Benjamin L. and Howard, Christopher B. (2021). Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product. Communications Biology, 4 (1) 390, 390. doi: 10.1038/s42003-021-01903-x

Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product

2021

Journal Article

Recombinant antibody engineering enables reversible binding for continuous protein biosensing

Fercher, Christian, Jones, Martina L., Mahler, Stephen M. and Corrie, Simon R (2021). Recombinant antibody engineering enables reversible binding for continuous protein biosensing. ACS Sensors, 6 (3) acssensors.0c01510, 764-776. doi: 10.1021/acssensors.0c01510

Recombinant antibody engineering enables reversible binding for continuous protein biosensing

2021

Journal Article

Incorporation of unnatural amino acid into antibody fragment for creating a stable antibody-drug conjugate

Wardiana, Andri, Jones, Martina L., Mahler, Stephen M. and Howard, Christopher B. (2021). Incorporation of unnatural amino acid into antibody fragment for creating a stable antibody-drug conjugate. Indonesian Journal of Pharmacy, 32 (1), 96-105. doi: 10.22146/ijp.1101

Incorporation of unnatural amino acid into antibody fragment for creating a stable antibody-drug conjugate

2021

Journal Article

Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications

MacDonald, Michael A., Nöbel, Matthias, Roche Recinos, Dinora, Martínez, Verónica S., Schulz, Benjamin L., Howard, Christopher B., Baker, Kym, Shave, Evan, Lee, Yih Yean, Marcellin, Esteban, Mahler, Stephen, Nielsen, Lars Keld and Munro, Trent (2021). Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications. Critical Reviews in Biotechnology, 42 (7), 1-17. doi: 10.1080/07388551.2021.1998821

Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications

2020

Journal Article

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells

Lund, Maria E., Howard, Christopher B., Thurecht, Kristofer J., Campbell, Douglas H., Mahler, Stephen M. and Walsh, Bradley J. (2020). A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells. BMC Cancer, 20 (1) 1214, 1214. doi: 10.1186/s12885-020-07562-1

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells

2020

Journal Article

Aggregates in blood filter chambers used from the plasma donations of anti-D donors: evaluation for monoclonal antibody discovery using phage display

McGowan, Eunike C., Flower, Robert L., Jones, Martina L., Irving, David O., Barnard, Ross T., Hyland, Catherine A., Mahler, Stephen M. and Bui, Xuan T. (2020). Aggregates in blood filter chambers used from the plasma donations of anti-D donors: evaluation for monoclonal antibody discovery using phage display. Blood Transfusion , 19 (1), 64-72. doi: 10.2450/2020.0093-20

Aggregates in blood filter chambers used from the plasma donations of anti-D donors: evaluation for monoclonal antibody discovery using phage display

2020

Journal Article

Controlling the biological fate of micellar nanoparticles: balancing stealth and targeting

Sivaram, Amal J., Wardiana, Andri, Alcantara, Sheilajen, Sonderegger, Stefan E., Fletcher, Nicholas L., Houston, Zachary H., Howard, Christopher B., Mahler, Stephen M., Alexander, Cameron, Kent, Stephen J., Bell, Craig A. and Thurecht, Kristofer J. (2020). Controlling the biological fate of micellar nanoparticles: balancing stealth and targeting. ACS Nano, 14 (10) acsnano.0c06033, 13739-13753. doi: 10.1021/acsnano.0c06033

Controlling the biological fate of micellar nanoparticles: balancing stealth and targeting

2020

Journal Article

‘Omics driven discoveries of gene targets for apoptosis attenuation in CHO cells

Orellana, Camila A., Martínez, Verónica S., MacDonald, Michael A., Henry, Matthew N., Gillard, Marianne, Gray, Peter P., Nielsen, Lars K., Mahler, Stephen and Marcellin, Esteban (2020). ‘Omics driven discoveries of gene targets for apoptosis attenuation in CHO cells. Biotechnology and Bioengineering, 118 (1) bit.27548, 481-490. doi: 10.1002/bit.27548

‘Omics driven discoveries of gene targets for apoptosis attenuation in CHO cells

2020

Journal Article

Phage display derived monoclonal antibodies: from bench to bedside

Alfaleh, Mohamed A., Alsaab, Hashem O., Mahmoud, Ahmad Bakur, Alkayyal, Almohanad A., Jones, Martina L., Mahler, Stephen M. and Hashem, Anwar M. (2020). Phage display derived monoclonal antibodies: from bench to bedside. Frontiers in Immunology, 11 1986, 1986. doi: 10.3389/fimmu.2020.01986

Phage display derived monoclonal antibodies: from bench to bedside

2020

Journal Article

Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets

Niamsuphap, Suchada, Fercher, Christian, Kumble, Sumukh, Huda, Pie, Mahler, Stephen M. and Howard, Christopher B. (2020). Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets. Expert Opinion on Drug Delivery, 17 (9), 1189-1211. doi: 10.1080/17425247.2020.1781088

Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets

Past funding

  • 2021 - 2023
    ACRF Facility for Targeted Radiometals in Cancer (AFTRiC)
    Australian Cancer Research Foundation
    Open grant
  • 2020 - 2021
    An integrated, multi-node bio-layer interferometry facility
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2019 - 2022
    Smart affinity membranes for manufacture of high value therapeutic proteins
    ARC Linkage Projects
    Open grant
  • 2019
    A versatile accurate mass, high resolution QTOF mass spectrometer for chemistry and proteomic applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019
    Advanced Nanoparticle, Colloid and Microparticle Characterisation and Precision Engineering Nanosystems Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019
    Cyto-Mine to accelerate Cell Line Development for Vaccines and Biopharmaceuticals
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019 - 2021
    Nanomedicine strategies for early detection and treatment of brain metastases
    NHMRC Project Grant
    Open grant
  • 2018
    Continuous chromatography system for advanced bioprocessing
    UQ Major Equipment and Infrastructure
    Open grant
  • 2018
    In vivo optical imaging into the next generation
    UQ Research Facilities Infrastructure Grants
    Open grant
  • 2017 - 2018
    Affinity Maturation of Anti-Lipopolysaccharide Antibody
    Innovation Connections
    Open grant
  • 2017 - 2018
    Provision of research services to Minomic International Ltd
    Minomic International Ltd
    Open grant
  • 2017 - 2023
    ARC Training Centre for Biopharmaceutical Innovation
    ARC Industrial Transformation Training Centres
    Open grant
  • 2016 - 2017
    EGFR targeted nanoparticle feasibility study
    Samyang Biopharmaceuticals Corporation
    Open grant
  • 2016 - 2019
    Next generation hybrid nanomaterials: bispecific antibody-targeted polymers
    ARC Linkage Projects
    Open grant
  • 2016 - 2017
    The biophysical characterisation of novel, recombinant bi-specific antibodies utilised in drug-delivery technology using Bio-layer Interferometry (Octet).
    Research Connections
    Open grant
  • 2016
    Exosome and Bio/Nanoparticle Characterisation Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016 - 2018
    Immuno-polymeric drugs for prostate cancer therapy
    NHMRC Project Grant
    Open grant
  • 2015
    A sensitive, high resolution QTOF mass spectrometer with nanoUPLC system for qualitative and quantitative biomolecule analysis.
    UQ Major Equipment and Infrastructure
    Open grant
  • 2015 - 2016
    Developing targeted EphA2 based imaging technology for glioblastoma
    Cure Brain Cancer Foundation
    Open grant
  • 2014 - 2023
    The National Biologics Facility - NCRIS 2013/2015/2016-17/2017-18/2018-19/2019-2023 (administered by Therapeutic Innovation Australia (TIA))
    Therapeutic Innovation Australia Limited
    Open grant
  • 2013 - 2015
    Safety assessment of anti-hendra virus antibody in humans
    Queensland Health
    Open grant
  • 2013
    QM6 Process Investigations
    UniQuest Pty Ltd
    Open grant
  • 2012 - 2015
    Single molecule spectroscopy-guided design of thermostable industrial enzymes
    ARC Linkage Projects
    Open grant
  • 2012 - 2015
    The first integrated multimodal assay for the ultrasensitive detection of dengue contamination of blood
    ARC Linkage Projects
    Open grant
  • 2012 - 2013
    Safety of Hendra virus anti-G glycoprotein monoclonal antibody in humans
    NHMRC Targeted Research
    Open grant
  • 2012 - 2015
    Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies
    ARC Linkage Projects
    Open grant
  • 2011
    Mass spectrometer for biomolecule discovery, structural analysis and quantification.
    UQ Major Equipment and Infrastructure
    Open grant
  • 2010 - 2012
    Development of an integrated technology platform for neural cell surface marker discovery and characterisation
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2010 - 2013
    Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases
    ARC Linkage Projects
    Open grant
  • 2010 - 2011
    High throughput isolation and expression of recombinant antibodies in mammalian cells
    UQ FirstLink Scheme
    Open grant
  • 2010
    Cost effective acquisition of an LC-MS/MS system to support CIPDD organics analysis and preclinical and clinical operations
    UQ Major Equipment and Infrastructure
    Open grant
  • 2009
    Robotics Instrumentation for High Throughput Sample preparation for Increased Productivity of the CIPDD/TetraQ's HPLC-MS/MS Systems for Quantitative Analysis of Organics in a Quality Systems NATA-Acc
    UQ Faculty Co-Funding
    Open grant
  • 2009
    Stem cell-based interface tissue engineering
    ARC Discovery Projects
    Open grant

Availability

Emeritus Professor Stephen Mahler is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

Contact Emeritus Professor Stephen Mahler directly for media enquiries about:

  • Antibodies
  • Biologic medicines
  • Pharmaceuticals

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au